Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Change in ELF Score at 12 Weeks in INTEGRIS-PSC Change in ELF Score at 12 Weeks in INTEGRIS-PSC Bexotegrast (PLN-74809)...
Read moreDetails